# The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC

Source: https://onco.cc/trials/nct05862610/  
OnCo record `nct05862610` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of trilaciclib in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, not yet recruiting.

## Summary

The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC is a phase 2, randomised interventional study registered as NCT05862610 by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with a registry enrolment figure of 150 participants, started 2023-07-30 and due to reach its primary completion in 2026-12-30. Interventions recorded: Trilaciclib plus chemotherapy; Chemotherapy. Conditions listed: Breast Neoplasm. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05862610
- Phase: 2
- Setting: A Prospective, Randomized, Controlled Phase II Clinical Study of Trilaciclib Combined With Standard Treatment Project As a Neoadjuvant Treatment For Triple Negative Breast Cancer
- Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT05862610: https://clinicaltrials.gov/study/NCT05862610

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- drugs: [Trilaciclib](https://onco.cc/drugs/trilaciclib/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05862610.json